MTOR and colorectal carcinoma: Notably, among non-hypermutated tumors, which represent 90% of all CRCs, approximately 59% of metastatic CRC patients exhibit mutations in the MAPK pathway, and 26.7% of these patients show concurrent mutations in the PI3K/AKT/mTOR pathway [20].